Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Modulators of BCL6 as ligand directed degraders
US12404239B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12404239-B2 |
| Application number | US-202318140129-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 27, 2023 |
| Priority date | Apr 28, 2022 |
| Publication date | Sep 2, 2025 |
| Grant date | Sep 2, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds and compositions thereof for modulating BCL6. In some embodiments, the compounds and compositions are provided for treatment of cancer or an autoimmune disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the following structural formula: or a pharmaceutically acceptable salt thereof. 2. A compound of the following structural formula: 3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 4. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable excipient. 5. A method of treating Non-Hodgkin's lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof. 6. A method of treating Diffuse Large B-cell Lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof. 7. A method of treating follicular lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof. 8. A method of treating Non-Hodgkin's lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 2 . 9. A method of treating Diffuse Large B-cell Lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 2 . 10. A method of treating follicular lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 2 .
Assignees
Inventors
Classifications
Optical isomers · CPC title
Antineoplastic agents · CPC title
- C07D401/14Primary
containing three or more hetero rings · CPC title
Ortho-condensed systems · CPC title
Bridged systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12404239B2 cover?
- Provided herein are compounds and compositions thereof for modulating BCL6. In some embodiments, the compounds and compositions are provided for treatment of cancer or an autoimmune disease.
- Who is the assignee on this patent?
- Celgene Corp, Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).